Project information
MEDGENET - Medical genomics and epigenomics network
(MEDGENET)
- Project Identification
- 692298
- Project Period
- 1/2016 - 12/2018
- Investor / Pogramme / Project type
-
European Union
- Horizon 2020
- Spreading excellence and widening participation
- MU Faculty or unit
- Central European Institute of Technology
- Cooperating Organization
-
European Molecular Biology Laboratory
Uppsala universitet
Centre for Research and Technology Hellas
The main goal of MEDGENET consortium is to use synergies and existing expertise in EU leading institutions such as EMBL, Uppsala University and CERTH to reinforce the productivity and competitiveness of the CEITEC in the field of medical genomics and epigenomics. We propose clear strategy based on combination of unique complementary skills present in partner institutions that will transform CEITEC into a key leader in the field. ERA Chair who recently joint CEITEC already initiated the transformational change of the institute and TWINNING framework will further support sharing her international contacts with other CEITEC researchers. MEDGENET aims to create well-educated taskforce of biomedical researchers, who will notably contribute to the development of new genomics and bioinformatics tools and their application in clinical practice. Proposed project will enable to establish the best practices for performing innovative and high-quality biomedical research and to strengthen CEITEC´s competence to translate the research results into high value-added clinical applications. Stimulation of knowledge exchange, implementation of cutting edge technologies and mastery of modern genomics and bioinformatics methodologies will have a direct impact on the overall research and innovation potential of CEITEC and will increase its visibility in the international scientific community.
Publications
Total number of publications: 52
2016
-
B cell receptor signaling activity is associated with evolution of TP53 defects in chronic lymphocytic leukemia
Year: 2016, type: Conference abstract
-
Cancer clonal evolution and mutational patterns in leukemia patients and development of software for variant calling.
Year: 2016, type: Conference abstract
-
Decreased expression of WNT3, a canonical Wnt pathway ligand is frequent in chronic lymphocytic leukemia progression and identifies patients with short treatment-free survival in mutated IGHV
Year: 2016, type: Conference abstract
-
Detailed analysis of chronic lymphocytic leukemia cases with single TP53 mutation
Year: 2016, type: Conference abstract
-
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 AXIS.
Year: 2016, type: Conference abstract
-
Introduction of nanopore sequencing to genomic core facility RNA workflows
Year: 2016, type: Conference abstract
-
Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status
Year: 2016, type: Conference abstract
-
MicroRNAs in the microenvironmental interactions of B cell leukemias.
Year: 2016, type: Conference abstract
-
Monoallelic TP53 abnormalities in CLL: do they really exist? The frequency and clinical impact of copy-neutral loss of heterozygosity
Year: 2016, type: Conference abstract
-
Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo
Year: 2016, type: Conference abstract